Abstract-Advances in wearable sensing and communications infrastructure have allowed the widespread development of prototype medical devices for patient monitoring. However, such devices have not penetrated into clinical practice, primarily due to a lack of research into "intelligent" analysis methods that are sufficiently robust to support large-scale deployment. Existing systems are typically plagued by large false-alarm rates, and an inability to cope with sensor artifact in a principled manner. This paper has two aims: 1) proposal of a novel, patient-personalized system for analysis and inference in the presence of data uncertainty, typically caused by sensor artifact and data incompleteness; 2) demonstration of the method using a large-scale clinical study in which 200 patients have been monitored using the proposed system. This latter provides much-needed evidence that personalized e-health monitoring is feasible within an actual clinical environment, at scale, and that the method is capable of improving patient outcomes via personalized healthcare.
this study has focussed on the use of "abnormality detection" or "novelty detection" methods [6] in machine learning, in which departures from an assumed state of physiological "normality" are identified, and brought to the attention of clinicians. This approach lends itself well to comparison with existing techniques mandated for use in U.K. hospitals, termed track and trigger systems, in which a heuristic "novelty score" is assigned to manual vital-sign observations made by clinicians, and where care is escalated if the score exceeds some predefined threshold [7] . Automated approaches using machine learning have been implemented with a wide range of techniques, including kernel estimates [8] , factorial switched Kalman filters [9] , extreme value theory [10] , [11] , neural networks [12] , and support vector machines [13] .
The limiting factor of existing techniques is typically deemed to be how they handle those commonly encountered periods of signal artifact, which arise due to patient movement, wearable sensor failure, and communication failures; currently, such periods are identified, and the incomplete or noisy vital-sign data replaced by a population-or patient-based mean for that channel [14] . This paper adopts a principled, probabilistic approach to vitalsign monitoring of patients, set within a Gaussian process framework for the first time, described in Section II. We will demonstrate that this method provides a step-change increment in the ability to perform patient-personalized monitoring in comparison to existing techniques. We introduce a large clinical study that we have undertaken to demonstrate that the method is applicable at scale, and in Section III, we present initial evidence of clinical validation for our proposed method. Section IV concludes with a discussion, and suggestions for future work.
II. METHOD-GAUSSIAN PROCESS FRAMEWORK
The Gaussian process (GP) framework offers a principled means of performing inference using the noisy, potentially artifactual, data obtained from wearable sensors used in e-health monitoring. Of fundamental importance is the notion of the GP as a distribution over functions, which is well suited to the analysis of our time series of patient physiological data, in which we perform inference over functions. This approach contrasts with conventional probabilistic approaches which define distributions over individual data points [8] , [14] .
We provide a brief overview to set notation, where more details may be found in [15] . For some observed dataset of physiological data over time intervals X = {x i | i = 1 . . . m}, we define a GP prior distribution over latent (unobserved) functions s = {s(
, where · is the 2 -norm, where σ l and σ s are hyperparameters giving the length-scale in the x-direction and the variance of s, respectively, and where the mean function μ s (x) = 0. We define a set of observed target physiological data which are assumed to be generated from some latent function t = {s(x i ) + ε | i = 1 . . . m}, with ε ∼ N (0, σ 2 t ) defining additive Gaussian noise over the latent function s.
For this prior GP distribution over functions, we may define the marginal likelihood (or "evidence") for some set of observed physiological data t given the set of inputs X
in which we have marginalized over the function values s, using the GP prior distribution over functions p(s|X) ∼ N (μ s (X), k(X, X)), and where the likelihood of the observed targets p(t|s, X) ∼ N (s, σ 2 t I). The log marginal likelihood corresponding to the integral can be found in closed form as a marginalized Gaussian, thanks to the consistency property of the GP
where we have used the notation K = k(X, X). We can perform a similar operation using posterior GPs, in which we have taken into account our observed physiological data over times X with their corresponding latent function values s and target observations t. If we wish to evaluate a function over n test points X * = {x * ,i | i = 1 . . . n}, we can apply a Bayesian formulation [15] to predict the n-dimensional vector of target physiological values t * corresponding to the test inputs X * using
In the above, we have the likelihood p(t * |s * ) = s(x * ) + ε as before; we have the posterior GP p(s|X, t), which we will consider below; and we have the joint posterior distribution over all functions, conditioned on the observed training data
where the mean function and covariance matrix in the above are, respectively
Due to the convenient analytical tractibility of the multivariate Gaussian distribution, the above integrals are determined in closed form.
For any given training set of physiological data {X, t}, we may therefore learn the posterior GP required in the above p(s|X, t), which is fully specified by its hyperparameters σ l , σ s , and σ t . The values of these hyperparameters have, for the work described in this paper, been determined to be those values that maximize the log marginal likelihood of the targets, which incorporates a tradeoff between model fit and model complexity [15] . For each vital sign, we have used independent GPs, each of which uses a square-exponential covariance function, zero mean function, and Gaussian likelihood. The choice of these parameters will be shown to be suitable for use with the physiological data obtained from our clinical study, described in Section III.
We adopt a patient-specific approach to the construction of GPs, allowing the personalization of the posterior distribution to those physiological data {X, t} acquired from each patient. After estimation of the hyperparameters from a patient's physiological data (such as, for example, heart rate and oxygen saturation measured through time using a wireless sensor), we may then use the GP to estimate reliably the distribution of values of the physiological data at any test points X * that we wish. We will demonstrate in the next section that this approach enables us a principled means of coping with periods of signal artifact, and with intervals in which one or more channels of data are incomplete (as occurs due to sensor detachment, communication failure, etc.).
III. RESULTS-CLINICAL STUDY

A. Clinical Need
We undertook a clinical study of 200 patients, approved by the local research ethics committee, in a postoperative ward for patients recovering from upper-gastrointestinal cancer surgery, in the Oxford University Hospitals NHS Trust, Oxford, U.K. This patient group is at particular risk of postsurgical complications (up to 20%), which can cause physiological deterioration followed by unplanned admission to an Intensive Care Unit. Such readmissions are typically accompanied by a high risk of mortality, which may be avoided if the physiological deterioration is acted upon early enough [7] . The current standard of care for such patients is periodic manual observation of vital signs, which suggests that personalized e-health monitoring approaches have the potential to improve patient outcomes by early detection of physiological deterioration.
B. e-Health Monitoring Infrastructure
Patients are connected to conventional bed-side monitors during the first day after their surgery. However, as is common for most hospital wards, the majority of patients are mobilized after the first day, to gain exercise by walking around the ward. This demonstrates the difficulty of monitoring the majority of patients in hospital (and at home), because they are ambulatory, and which therefore strongly motivates the use of wearable monitors to track patient condition.
Continuous wearable monitoring devices are widely available, despite the disadvantages of high false-alarm rates [7] , and the system deployed in the study described by this paper used mobile pulse oximeters manufactured by Nonin Medical, Inc. (for the acquisition of the photoplethysmogram or PPG, from which oxygen saturation, SpO2, and heart rate, HR, may be derived) and mobile ECG sensors manufactured by Corscience GmbH & Co. KG (for the acquisition of the ECG, from which HR may be derived). We note that the factory-provided (univariate) alarm functions of these wearable monitors were deactivated, and the devices were used only for continuous data acquisition, to which the machine learning method described in Section II was then applied.
These wearable devices were configured to communicate via Bluetooth to a patient-worn PDA, which collected ECG at 256 Hz and the PPG at 75 Hz. These waveforms, along with derived estimates of HR and SpO2, were transmitted to a central server via Wi-Fi. The central station stored data along with anonymized patient information for analysis. Manual measurements of blood pressure and respirator rate (RR) made by the ward staff were entered into the patient PDA, automatically transmitted to the central station, and then associated with the continuous data described earlier.
C. Personalized GPs
Two hundred patients were entered into our study, 105 of which were connected to bedside monitors as part of their standard of care. One hundred and sixty five of the 200 patients were subsequently connected to wearable monitors; the remaining 35 patients either refused to wear the devices, or did not wear them for other reasons. Total monitoring duration for the patients connected to bedside monitors was 120.4 days; total monitoring duration for the patients connected to wearable monitors was 285.4 days. During the clinical study, 16 503 manual observations of physiological data were made by ward nurses, which were merged into the time-series of continuous, automatically acquired data, as described earlier. The total quantity of physiological data was 63.8 GB-a large volume that motivates robust automated analysis.
In order to demonstrate the suitability of the GP framework for providing personalized models of physiological data, we considered the union of all data acquired from bedside and wearable monitors for each patient independently. The resulting datasets for each of the 200 patients were each randomly partitioned 75%:25% into training and test sets, respectively. For each patient, the training set was used in tenfold cross validation to determine the values of the hyperparameters for a personalized GP (as described in Section II), and, for comparison, a personalized support vector machine regressor, or SVR [16] . The latter represents a popular discriminative kernel-based approach to regression, the details of which have been described frequently in the literature, and which are omitted for brevity. The mean-squared error (MSE) between each patient's test set and the output of the GP and the SVR were then compared with 1) the population mean in each channel, representing existing practice as described in Section I and 2) the patient-specific mean in each channel, obtained from each patient's training set. Fig. 1 shows MSE values for the GP, the SVR, and use of the population-and patient-specific mean, where summary statistics for each are given in Table I . The latter shows the mean MSE, one standard deviation in MSE, and the interquartile range in MSE over the 200 patients as μ E , σ E , and IQR E , respectively, for all four methods (where the population-and patient-specific mean are E 1 and E 2 , respectively). It may be seen that the personalized GP and SVR methods result in the lowest overall MSE on the independent test sets for each patient, over all 200 patients. There are similarities between the formulations of the GP and SVR methods [15] , but we note that, while the methods offer similar performance on the test data, the former permits a probabilistic approach, while the latter does not. In particular, the GP estimates the distribution of data at each point, providing a confidence bound on the estimated value of physiological data. This is illustrated by the personalized GP shown in Fig. 2 , where it may be seen that the confidence interval for the GP regression corresponds to manual observations taken during a period of data incompleteness caused by sensor failure. As shown in Fig. 2 , the GP performs interpolation between whichever data are available, independent of the length of the gaps between them. Therefore, there is no need to identify gaps explicitly.
This demonstrates that both the personalized GP and the SVR can produce time-series models that accurately model the behavior of our physiological data acquired from e-health monitors. In periods of incomplete or artifactual data, these accurate regressions can, therefore, be used to estimate the true value of , against time (measured in time before ICU admission, which occurred at the end of the period shown). Novelty scores assigned using [10] with and without GP regression are shown in red and blue in the lower plot, respectively. Novelty alerts were generated at times t G P and t 0 for the system with and without GP regression, respectively. the data and, in the case of the personalized GP, the distribution over those estimated values. Fig. 3 shows the application of the GP when used to perform subsequent novelty detection on test data for a patient, using time series of physiological data that have had periods of artifact and incomplete data augmented by personalized GP regression. Here, the patient suffered a readmission to the ICU at the end of the period shown, and for whom we therefore require early detection of deterioration. A novelty detection algorithm has previously been described [10] for mapping multivariate physiological values onto novelty scores, and which is here used to illustrate the proof-of-concept motivating the use of the personalized GP. Novelty scores are defined as z(x) = − log p(x), where p(x) is a density estimate constructed using "normal" patient data. Without GP regression, novelty scores exceed an alerting threshold approximately 3.5 h before the ICU readmission (t 0 in the figure) ; using GP regression, novelty scores consistently exceed an alerting threshold approximately 21.5 h before the ICU readmission t GP , representing a highly significant increase in the amount of early warning provided. This occurs because the GP provides robust estimates of the artifactual and incomplete patient data prior to the event, which would otherwise have been replaced by the population mean for each channel of data, and which would therefore have caused the patient to look incorrectly "normal" prior to the ICU readmission. Over all seven "abnormal" patients for whom we have data, t GP preceded t 0 by a median of 13.4 h. However, we note that the number of "abnormal" patients is statistically insignificant, given the incidence of ICU readmission. A follow-up clinical study has been planned to collect data for a larger number of "abnormal" patients.
IV. DISCUSSION
We have described a novel, personalized formulation for the handling of time-series of physiological patient data, cast within a GP regression framework. Over a large clinical study, the method has been demonstrated (via MSE from independent test data) to outperform conventional methods of coping with artifactual or missing data. A proof-of-concept has been included showing that existing multivariate novelty detection algorithms can result in substantial increases in early warning of patient deterioration, because artifactual or missing data no longer need to be replaced by population means, as is conventional practice. An on-going clinical study is underway to collect further data to provide thorough clinical validation of our methodology.
